Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 203.0% in January

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 229,817 shares, a growth of 203.0% from the January 15th total of 75,842 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 1,165,477 shares, the days-to-cover ratio is currently 0.2 days. Based on an average trading volume of 1,165,477 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Daiichi Sankyo Trading Up 1.4%

Shares of Daiichi Sankyo stock opened at $19.37 on Thursday. Daiichi Sankyo has a fifty-two week low of $17.80 and a fifty-two week high of $28.21. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. The firm has a market capitalization of $36.69 billion and a price-to-earnings ratio of 16.99. The stock has a 50 day moving average of $20.94 and a 200 day moving average of $23.21.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings results on Thursday, January 29th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.25 by $0.05. The business had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.88 billion. Daiichi Sankyo had a return on equity of 18.39% and a net margin of 15.40%. As a group, research analysts predict that Daiichi Sankyo will post 0.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Daiichi Sankyo presently has an average rating of “Moderate Buy”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.